Platelet Rich Plasma Therapies – Medicare Advantage Medical Policy | UHC Coverage Update

UnitedHealthcare modified its platelet-rich plasma coverage policy effective November 2, 2025, reshaping how billing teams handle CPT 0232T and HCPCS codes G0460, G0465, and P9020 across wound care and musculoskeletal indications.

The updated policy locks UHC's PRP coverage framework directly to CMS National Coverage Determinations and local coverage determinations—meaning your reimbursement path now runs through CMS compliance before UHC commercial policy even enters the picture. If your practice bills PRP injections or applications for diabetic wounds, non-diabetic chronic wounds, or musculoskeletal conditions, this change affects your claim submission process starting November 2, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	UnitedHealthcare
Policy	Platelet Rich Plasma Therapies
Policy Code	N/A
Change Type	Modified
Effective Date	November 2, 2025
Impact Level	High
Specialties Affected	Wound care, orthopedics, sports medicine, podiatry, physical medicine & rehabilitation
Key Action	Audit your PRP billing against applicable CMS NCDs and LCDs before submitting claims under CPT 0232T, G0460, or G0465

---

UnitedHealthcare Platelet-Rich Plasma Coverage Criteria and Medical Necessity Requirements 2025

The UnitedHealthcare platelet-rich plasma coverage policy now explicitly defers to CMS coverage frameworks as the primary authority. That's a meaningful structural change. It means medical necessity under this policy isn't defined by a single UHC document—it's defined by whichever NCD or LCD governs your patient's specific indication and geography.

Here's how the framework breaks down.

Diabetic chronic wounds: CMS NCD 270.3 (Blood-Derived Products for Chronic Non-Healing Wounds) controls coverage. HCPCS G0465 is the relevant billing code. Medical necessity criteria come directly from NCD 270.3—not from UHC's commercial policy. If your MAC has issued an LCD that conflicts with or supplements the NCD, the NCD takes precedence.

Non-diabetic chronic wounds: This is where regional variation bites you. LCDs and Local Coverage Articles from your Medicare Administrative Contractor govern coverage for non-diabetic chronic non-healing wounds not addressed by NCD 270.3. HCPCS G0460 applies here. Your coverage determination will differ depending on which MAC jurisdiction you're in. If no LCD exists in your state or territory, UHC directs you to its commercial medical policy titled Prolotherapy and Platelet Rich Plasma Therapies.

Musculoskeletal injuries and joint conditions: LCDs and LCAs also govern PRP injections and applications for musculoskeletal use. CPT 0232T—injection(s) of platelet-rich plasma, any site, including image guidance, harvesting, and preparation—is the primary code here. Compliance with applicable LCDs is required where they exist.

The real issue with this structure is that it creates a tiered coverage policy. Your billing team can't apply one uniform standard across PRP claims. You need to know the indication, the patient's insurance product, and the relevant MAC jurisdiction before you can determine whether a claim will clear.

Prior authorization requirements aren't explicitly detailed in this policy update, but given the LCD-dependent structure, check your MAC's LCD for prior auth requirements before submitting claims. Several MAC jurisdictions require prior authorization or detailed documentation review for PRP services—and a missing prior auth is one of the fastest routes to claim denial.

---

UnitedHealthcare Platelet-Rich Plasma Exclusions and Non-Covered Indications

HCPCS P9020—platelet-rich plasma, each unit—is explicitly designated as non-covered under this policy. That designation is clear and unambiguous. Do not bill P9020 expecting reimbursement under UHC.

The broader exclusion logic here ties back to the LCD framework. Any PRP indication not covered by NCD 270.3 and not addressed by a relevant LCD defaults to UHC's commercial medical policy for Prolotherapy and Platelet Rich Plasma Therapies. That commercial policy contains its own experimental and investigational designations. If you're billing PRP for indications outside diabetic wounds, non-diabetic chronic wounds, or the musculoskeletal applications addressed by your MAC's LCD, you're likely in non-covered territory.

This matters for specialties that use PRP for cosmetic or aesthetic indications, hair restoration, or other off-label applications. None of those fall under NCD 270.3 or typical musculoskeletal LCDs. Expect denial.

---

Coverage Indications at a Glance

---

UnitedHealthcare Platelet-Rich Plasma Billing Guidelines and Action Items 2025

The effective date of November 2, 2025 is already here. If you haven't audited your PRP billing processes against this updated structure, do it now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Platelet-Rich Plasma Therapies Under UHC Policy

Covered CPT Codes (When LCD Selection Criteria Are Met)

Code	Type	Description Copy
0232T	CPT	Injection(s), platelet-rich plasma, any site, including image guidance, harvesting, and preparation

Covered HCPCS Codes (Indication-Specific)

Code	Type	Description	Governing Authority Copy
G0460	HCPCS	Autologous platelet-rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers	Applicable MAC LCD/LCA
G0465	HCPCS	Autologous platelet-rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers	CMS NCD 270.3

Not Covered / Explicitly Excluded Codes

Code	Type	Description	Reason Copy
P9020	HCPCS	Platelet-rich plasma, each unit	Explicitly designated Non-Covered under UHC policy

No ICD-10-CM diagnosis codes are specified in this policy update. Applicable diagnosis codes are determined by the governing NCD or LCD for each indication. Reference NCD 270.3 for diabetic wound diagnoses and your MAC's LCD for musculoskeletal and non-diabetic wound diagnoses.

---

A note on platelet-rich plasma billing under this structure: the code selection is straightforward. The complexity is in the prerequisite work—knowing your LCD, verifying medical necessity documentation, and confirming prior authorization status before the claim goes out. Billing teams that treat PRP claims as routine procedural billing will see denial rates climb. The ones that build indication-specific workflows for 0232T, G0460, and G0465 will hold their clean claim rate.

This is a similar pattern to how CMS structured coverage for other biologics and blood-derived products—coverage exists, but it's gated behind jurisdiction-specific local coverage determinations that your billing team has to actively track. The UHC policy change just makes that dependency explicit rather than implied.

---